On March 27, 2026, InMed Pharmaceuticals Inc. (NASDAQ: INM) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC, indicating that the closing bid price of the company's common shares had fallen below the minimum requirement of $1.00 per share for continued listing on The Nasdaq Capital Market. This deficiency was noted over a period of 30 consecutive trading days from February 11, 2026, to March 26, 2026. The notice does not immediately impact the listing of InMed's common shares, which will continue to trade on The Nasdaq Capital Market, provided the company meets other listing requirements. InMed has a grace period of 180 calendar days to regain compliance by ensuring that the closing bid price meets or exceeds the $1.00 threshold for at least 10 consecutive business days during this period. The company is actively monitoring its share price and exploring options to address this issue. If compliance is not achieved within the grace period, InMed may be eligible for an additional 180-day extension, contingent upon meeting other listing standards. However, if the company fails to demonstrate compliance, it may face delisting from Nasdaq. InMed's management has expressed its commitment to addressing this situation and maintaining its listing status.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.